195 related articles for article (PubMed ID: 26049002)
1. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate.
Zeng W; Tan AC; Horrocks K; Jackson DC
Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002
[TBL] [Abstract][Full Text] [Related]
2. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
3. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody.
Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC
Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411
[TBL] [Abstract][Full Text] [Related]
4. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
5. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
Liu W; Zou P; Chen YH
Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
[TBL] [Abstract][Full Text] [Related]
7. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
[TBL] [Abstract][Full Text] [Related]
8. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
Zhou C; Zhou L; Chen YH
Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
[TBL] [Abstract][Full Text] [Related]
9. Characterization of immunity induced by M2e of influenza virus.
Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
[TBL] [Abstract][Full Text] [Related]
10. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
[TBL] [Abstract][Full Text] [Related]
11. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
12. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
13. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
14. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens.
Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW
Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342
[TBL] [Abstract][Full Text] [Related]
16. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
Kaminaka K; Matsuda J; Nozaki C
Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
[TBL] [Abstract][Full Text] [Related]
17. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.
Heinen PP; Rijsewijk FA; de Boer-Luijtze EA; Bianchi ATJ
J Gen Virol; 2002 Aug; 83(Pt 8):1851-1859. PubMed ID: 12124449
[TBL] [Abstract][Full Text] [Related]
19. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine.
Adler-Moore J; Munoz M; Kim H; Romero J; Tumpey T; Zeng H; Petro C; Ernst W; Kosina S; Jimenez G; Fujii G
Vaccine; 2011 Jun; 29(27):4460-8. PubMed ID: 21545821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
